Disease in Agriculture — Animals

Q1 — Sample Band 6 response (8 marks), annotated

Foot-and-mouth disease is caused by Aphthovirus, a virus belonging to the family Picornaviridae. As a non-cellular pathogen it requires a living host cell to replicate and cannot be treated with antibiotics. The virus is extraordinarily contagious and spreads via multiple routes: direct nose-to-nose contact between animals, short-range aerosol (the virus has been recorded travelling several kilometres in favourable wind conditions), and indirectly via fomites such as contaminated vehicles, equipment and the clothing and footwear of people moving between farms. [1 — pathogen classified + transmission mechanisms]

The economic effects of an FMD outbreak fall into two distinct categories. Direct effects include the loss of productive animals through culling, reduced productivity during outbreak periods, and decontamination costs. In the UK 2001 outbreak, direct agricultural losses were estimated at £2.7 billion, representing the value of approximately 6 million culled animals, decontamination, and lost production. [1 — direct effects with specific UK figure]

Indirect effects arise from the disease’s status as a notifiable disease with immediate international implications. They include import bans by trading partners (who require FMD-free certification for all livestock products), movement restrictions that prevent normal livestock trade domestically, loss of consumer confidence in the broader agricultural sector, and government emergency surveillance and compensation costs. In the UK 2001 outbreak, these indirect effects — particularly lost tourism when countryside access was closed — brought the total economic cost to £8 billion, roughly three times the direct agricultural loss. [1 — indirect effects with UK figures showing indirect > direct]

For Australia, Stimulus 2 shows that export markets requiring FMD-free certification collectively represent approximately $9.8 billion in annual export revenue, with Japan, China, South Korea, the United States and the Middle East among the key markets. These are premium markets that pay higher prices partly because Australian livestock products carry disease-free certification. A single confirmed FMD detection in Australia would trigger immediate import bans across all these markets simultaneously. Unlike the UK, which could retain some European trade, Australia’s geographic market structure means a complete export ban would be close to total. Market restoration after FMD eradication typically requires years of disease-free monitoring before importing countries lift bans — meaning revenue losses extend well beyond the outbreak period itself. [1 — Australia-specific severity using Stimulus 2 market data]

It is also notable that the indirect effects would dwarf direct effects even more extremely in Australia than in the UK. Australia exports over 70% of its beef production; the UK, as a member of a continental trading bloc, had alternative markets that were relatively accessible despite FMD status. Australian producers have no equivalent alternative export market of equivalent value to their premium Asian and Middle Eastern buyers. [1 — Australia’s greater vulnerability relative to UK]

Assessing the economic justification of active biosecurity: Australia’s annual investment in border biosecurity, the National Livestock Identification System (NLIS), and rapid-response capacity is estimated at several hundred million dollars per year. This investment protects approximately $9.8 billion in annual export revenue (from Stimulus 2 alone) plus the domestic market premium commanded by disease-free status. Even a conservative estimate of total FMD-related export market value at $15–20 billion annually means that annual biosecurity investment represents approximately 2–3% of the revenue it protects. The 2001 UK outbreak demonstrated that not maintaining active biosecurity allowed a disease to spread from a single abattoir to national scale within weeks; the lesson is that passive geographic isolation — FMD not being currently present — is not equivalent to active protection. [1 — economic justification of biosecurity investment]

Furthermore, maintaining biosecurity infrastructure in the absence of disease is exponentially cheaper than eradicating an established incursion. The UK example demonstrates this clearly: prevention costs a fraction of the £8 billion total cost of a single outbreak. Active surveillance systems (such as NLIS livestock traceability) also enable rapid identification of animal movements in an early outbreak, potentially limiting spread and confining export bans to a shorter duration. [1 — prevention vs eradication economics]

In conclusion, the economic justification for maintaining active biosecurity is overwhelming. Australia’s disease-free status is not a passive fact of geography but an actively maintained competitive advantage that underpins $9.8 billion or more in annual export revenue. The absence of FMD since 1872 is the evidence that the investment is working, not a reason to reduce it. [1 — evaluative judgement]

Marking criteria:

• 1 mark — Classifies FMD pathogen as a virus (Aphthovirus / Picornaviridae) and describes at least two routes of transmission (e.g. aerosol, direct contact, fomites).
• 1 mark — Correctly identifies direct economic effects (culling, production loss, decontamination) with a specific UK 2001 figure (e.g. £2.7B direct).
• 1 mark — Correctly identifies indirect effects (export bans, movement restrictions, consumer confidence loss) with reference to UK total of £8B — demonstrating indirect exceeds direct.
• 1 mark — Uses Stimulus 2 data to explain why Australia’s indirect effects would be particularly severe (e.g. cites at least one specific market value and explains simultaneous ban across all markets).
• 1 mark — Demonstrates understanding that Australia’s export dependence makes it uniquely vulnerable compared to the UK (e.g. ~70% beef exported; no equivalent alternative markets).
• 1 mark — Assesses the economic justification of biosecurity investment, linking biosecurity costs to the scale of protected export revenue (or prevention vs eradication cost argument).
• 1 mark — Explains why passive geographic isolation is insufficient (active biosecurity required — travellers, contaminated products, aerosol), linking to the NLIS or rapid-response capability.
• 1 mark — Reaches an explicit evaluative judgement supporting ongoing active biosecurity investment, using lesson language (disease-free status as a competitive advantage).

Q2 — Sample Band 6 response (7 marks), annotated

BVD is caused by Pestivirus, a non-cellular pathogen (virus) that replicates within host cells. The defining epidemiological challenge of BVD is the persistently infected (PI) animal: calves infected with the virus in utero before approximately 120 days of gestation develop immunotolerance — their immune systems recognise the virus as “self” and never mount a neutralising antibody response. As a result, PI animals shed enormous quantities of infectious virus continuously throughout their lives without displaying clinical signs. Because they appear clinically normal, they move through the herd (and are bought and sold) without being identified as disease sources, continuously exposing herd mates to high viral titres. [1 — PI mechanism explained with immunotolerance]

Against the criterion of short-term producer cost, Strategy 1 (“do nothing”) appears attractive: there is no testing or vaccination expense, and no need to replace culled animals. Strategy 2 (test-and-cull) imposes an immediate cost of $15–$45 per animal tested plus the replacement cost of any PI animals identified and removed from the herd. For a 1,000-head breeding herd, initial testing might cost $15,000–$45,000, and PI prevalence of 1–2% means 10–20 culls plus replacements. This is a significant short-term cost burden for smaller producers. [1 — short-term cost criterion assessed for both strategies]

Against the criterion of long-term loss reduction, Strategy 2 is decisively superior. The $100–$114 million annual national cost of endemic BVD accumulates continuously under Strategy 1. A 10,000-head commercial enterprise contributing proportionally might expect annual BVD-attributable losses of $80,000–$100,000/year in reduced weaning rates, slower live-weight gain, treatment of secondary infections, and reproductive failure. Published economic models show that removing PI animals reduces BVD-attributable losses by 80–90% within 3–5 years. At $90,000/year loss reduced by 85%, that is $76,500/year saved. Against an initial test-and-cull cost of perhaps $30,000, the payback period is less than six months — for a large commercial enterprise, Strategy 2 is clearly economically superior in the medium term. [1 — long-term loss reduction criterion, with numbers]

Against the criterion of herd health and welfare, Strategy 1 fails progressively. PI animals continuously challenge the immune systems of herd mates, making those animals more susceptible to secondary bacterial infections (respiratory disease, enteritis), increasing treatment costs and mortality beyond the directly BVD-attributable losses recorded. Strategy 2, by removing the viral reservoir, improves general herd immune competence and reduces overall veterinary expenditure over time. [1 — herd welfare criterion]

The critical caveat is scale. For a small producer with 50–80 breeding cows and limited cash flow, the upfront cost of testing and replacement may be prohibitive even where the long-term return is positive. In this context, a phased approach — testing purchased stock before introduction, and testing the breeding cohort progressively — reduces the immediate cost burden while still delivering most of the epidemiological benefit of identifying and removing PI animals. [1 — scale-dependent recommendation acknowledging small vs large producer]

Strategy 1 also carries a risk not immediately obvious from the cost figures: the ongoing presence of PI animals creates a permanent reservoir from which BVD can re-enter any previously clean property through bought-in stock. Without testing, a producer cannot know whether a newly purchased animal is PI, and a single PI animal introduced into a naïve herd can infect virtually all pregnant cows, producing a new cohort of PI calves and resetting any informal disease reduction achieved over prior years. [1 — risk of PI animals in purchased stock under Strategy 1]

My recommendation is that Strategy 2 is the appropriate default for any commercial beef or dairy enterprise above approximately 200 head, where the return on testing investment is clearly positive within one production cycle. For smaller operations, a minimum form of Strategy 2 — mandatory testing of all purchased cattle before herd introduction, combined with strategic annual testing of calves — is recommended as a cost-effective middle path. Strategy 1 (“do nothing”) cannot be recommended for any herd where BVD prevalence is suspected, because the long-term losses consistently exceed the cost of identification and removal by a wide margin. [1 — justified, scale-sensitive recommendation]

Marking criteria:

• 1 mark — Explains the PI mechanism correctly: in utero infection leads to immunotolerance, so PI animals shed virus continuously without clinical signs, making them invisible sources of ongoing herd infection.
• 1 mark — Assesses Strategy 1 vs Strategy 2 on short-term cost (Strategy 1 = lower upfront; Strategy 2 = testing + replacement cost) with appropriate figures or proportional reasoning.
• 1 mark — Assesses both strategies on long-term loss reduction, demonstrating that Strategy 2’s 80–90% reduction in BVD losses delivers a positive net return for commercial herds within a defined timeframe.
• 1 mark — Assesses either herd welfare/secondary disease burden or the risk of PI re-introduction via purchased stock as a third criterion.
• 1 mark — Acknowledges that the optimal strategy differs by scale (small vs large operation) and justifies why.
• 1 mark — Identifies the risk of relying on Strategy 1: PI animals in purchased stock can reinfect any informally improved herd, rendering informal gains temporary.
• 1 mark — Reaches an explicitly justified recommendation that is not a simple “Strategy 2 wins” but integrates scale-sensitivity and acknowledges the conditions under which a phased or intermediate approach is appropriate.